Cited by 165Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

Open access
Fowler, Christopher, Rainey-Smith, Stephanie R., Bird, Sabine, Bomke, Julia, Bourgeat, Pierrick, Brown, Belinda M., Burnham, Samantha C., Bush, Ashley I. +56 more·2021·Journal of Alzheimer's Disease Reports

Abstract

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in 2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild cognitive impairment (MCI), and 211 with Alzheimer’s disease dementia (AD)) as an ‘Inception cohort’ who underwent detailed ssessments every 18 months. Over the past decade, an additional 1247 subjects have been added as an ‘Enrichment cohort’ (as of 10 April 2019). Objective: Here we provide an overview of these Inception and Enrichment cohorts of more than 8,500 person-years of investigation. Methods: Participants underwent reassessment every 18 months including comprehensive cognitive testing, neuroimaging (magnetic resonance imaging, MRI; positron emission tomography, PET), biofluid biomarkers and lifestyle evaluations. Results: AIBL has made major contributions to the understanding of the natural history of AD, with cognitive and biological definitions of its three major stages: preclinical, prodromal and clinical. Early deployment of Aβ-amyloid and tau molecular PET imaging and the development of more sensitive and specific blood tests have facilitated the assessment of genetic and environmental factors which affect age at onset and rates of progression. Conclusion: This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. Harmonization with similar large longitudinal cohort studies is underway to further these aims.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/adr-210005

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [10]Delis D, Kramer J, Kaplan E, Ober B (2000) California Verbal Learning Test-Second Edition., The Psychological Corporation, San Antonio, TX.
  2. [111]Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, Maruff P (2016) Abeta-related memory decline in APOE epsilon4 noncarriers: Implications for Alzheimer disease. Neurology 86, 1635– 1642. 27029632

Cited by

Sorted by citations

Authors
Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., Doecke, J., Doré, V., Ellis, K. A., Evered, L., Fazlollahi, A., Fripp, J., Gardener, S. L., Gibson, S., Grenfell, R., Harrison, E., Head, R., Jin, L., Kamer, A., Lamb, F., Lautenschlager, N. T., Laws, S. M., Li, Q.-X., Lim, L., Lim, Y. Y., Louey, A., Macaulay, S. L., Mackintosh, L., Martins, R. N., Maruff, P., Masters, C. L., McBride, S., Milicic, L., Peretti, M., Pertile, K., Porter, T., Radler, M., Rembach, A., Robertson, J., Rodrigues, M., Rowe, C. C., Rumble, R., Salvado, O., Savage, G., Silbert, B., Soh, M., Sohrabi, H. R., Taddei, K., Taddei, T., Thai, C., Trounson, B., Tyrrell, R., Vacher, M., Varghese, S., Villemagne, V. L., Weinborn, M., Woodward, M., Xia, Y., Ames, D., & the AIBL investigators
Affiliations
  • The University of Melbourne (AU)
  • Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
  • Edith Cowan University (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
  • Murdoch University (AU)
  • Department of Anaesthesia and Acute Pain Medicine, St Vincent’s Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia
  • Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
  • Austin Hospital (AU)
  • Cogstate Limited, Melbourne, VIC, Australia
  • Macquarie University (AU)
  • St Vincent's Hospital Melbourne (AU)
  • University of Pittsburgh (US)
Corresponding author
Masters, Colin L.
Venue
Journal of Alzheimer's Disease Reports
Published
2021-03-11
Volume
5
Issue
1
Pages
443-468
ISSN
2542-4823 (ISSN-L)
OpenAlex
W3167322081
Cited by
164
References
127
Citations by year
2026: 27 · 2025: 42 · 2024: 41 · 2023: 21 · 2022: 30 · 2021: 3
FWCI
17.03
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease Reports (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by-nc)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
  • Murdoch University Research Portal (submittedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc)
  • Australasian Journal of Paramedicine (submittedVersion, cc-by-nc)
  • Edith Cowan University Research Online (Edith Cowan University) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Elan
  • Avid Radiopharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, mild cognitive impairment, preclinical Alzheimer's disease, prodromal Alzheimer's disease, amyloid PET, tau PET, blood biomarkers, neuroimaging, cognitive decline, older adults, longitudinal cohort, disease progression, age of onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review